MCID: OBS001
MIFTS: 53

Obstructive Jaundice

Categories: Gastrointestinal diseases, Genetic diseases

Aliases & Classifications for Obstructive Jaundice

MalaCards integrated aliases for Obstructive Jaundice:

Name: Obstructive Jaundice 12 15
Jaundice, Obstructive 44 73
Obstructive Hyperbilirubinemia 12
Cholestatic Jaundice Syndrome 12
Cholestatic Jaundice 12
Jaundice Obstructive 55
Jaundice Cholestatic 55

Classifications:



External Ids:

Disease Ontology 12 DOID:13603
MeSH 44 D041781
NCIt 50 C34742
SNOMED-CT 68 44018007 59848001
UMLS 73 C0022354

Summaries for Obstructive Jaundice

MalaCards based summary : Obstructive Jaundice, also known as jaundice, obstructive, is related to acute pancreatitis and iga glomerulonephritis, and has symptoms including icterus and jaundice (not of newborn). An important gene associated with Obstructive Jaundice is ALPP (Alkaline Phosphatase, Placental), and among its related pathways/superpathways are Immune response IFN alpha/beta signaling pathway and IL-1 Family Signaling Pathways. The drugs Lactulose and Ofloxacin have been mentioned in the context of this disorder. Affiliated tissues include liver, pancreas and lung, and related phenotypes are growth/size/body region and homeostasis/metabolism

Related Diseases for Obstructive Jaundice

Diseases in the Obstructive Jaundice family:

Jaundice, Familial Obstructive, of Infancy

Diseases related to Obstructive Jaundice via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 494)
# Related Disease Score Top Affiliating Genes
1 acute pancreatitis 30.3 CRP CXCL8 IL6
2 iga glomerulonephritis 30.2 ALB IL6 REN
3 cholecystitis 30.2 ALB F2 GPT
4 choledocholithiasis 30.2 ALB ALPP F2 GPT SLC17A5
5 hepatitis 30.2 F2 GGT1 GPT SLC17A5 TNF
6 autoimmune hepatitis 30.1 F2 GGT1 GPT
7 acute cholangitis 30.0 CRP IL6
8 biliary atresia 30.0 ALB GPT HGF
9 portal hypertension 29.9 ALB EDN1 F2 GPT TNF
10 hepatorenal syndrome 29.8 ALB EDN1 F2 REN
11 sclerosing cholangitis 29.8 ALB GGT1 GPBAR1 TNF
12 biliary tract disease 29.8 ALB F2 GGT1 GPBAR1 SLC25A13
13 fascioliasis 29.7 ALB ALPP GPT SLC17A5
14 abdominal tuberculosis 29.7 ALB CRP F2
15 monocytic leukemia 29.7 CXCL8 IL6 TNF
16 infantile liver failure syndrome 1 29.7 ALB F2 GPT SLC17A5
17 viral hepatitis 29.6 ALB F2 GGT1 GPT SLC17A5 TNF
18 opisthorchiasis 29.6 CXCL8 GPT TNF
19 cholestasis 29.5 ALPP F2 GGT1 GPT SLC25A13
20 acute cystitis 29.5 ALB CRP CXCL8 IL6
21 hepatic tuberculosis 29.5 ALB ALPP F2 GGT1 GPT
22 alcoholic liver cirrhosis 29.5 ALB CXCL8 F2 SLC17A5
23 cholangitis 29.4 ALB CRP F2 GGT1 GPBAR1 GPT
24 gastroenteritis 29.4 ALB CRP CXCL8 IL6 TNF
25 diabetes mellitus 29.4 ALB CRP EDN1 IL6 REN TNF
26 myeloma, multiple 29.3 ALB CRP CXCL8 HGF IL6 TNF
27 liver disease 29.2 ALB ALPP F2 GGT1 GPT HGF
28 ulcerative colitis 29.2 CRP CXCL8 IL6 TNF
29 liver cirrhosis 29.1 ALB EDN1 F2 GGT1 GPT HGF
30 malaria 29.1 ALB CRP CXCL8 EDN1 IL6 TNF
31 peritonitis 28.9 ALB CRP CXCL8 F2 IL6 TNF
32 mirizzi syndrome 11.4
33 biliary malformation with renal tubular insufficiency 11.4
34 cholestasis, benign recurrent intrahepatic, 1 11.3
35 acth deficiency, isolated 11.2
36 cholestasis, benign recurrent intrahepatic, 2 11.2
37 bile acid synthesis defect, congenital, 1 11.2
38 congenital disorder of glycosylation, type ik 11.2
39 hepatocellular carcinoma 10.5
40 pancreatitis 10.5
41 lymphoma 10.5
42 adenocarcinoma 10.3
43 acute adrenal insufficiency 10.3 IL6 REN
44 congenital hepatic fibrosis 10.3 REN SLC17A5
45 pyridoxine deficiency 10.3 GPT SLC17A5
46 paraquat poisoning 10.3 GPT SLC17A5
47 benign essential hypertension 10.3 ALB REN
48 kidney papillary necrosis 10.3 ALB REN
49 retinitis pigmentosa 55 10.3 IL6 TNF
50 hypertension, diastolic 10.3 GGT1 REN

Graphical network of the top 20 diseases related to Obstructive Jaundice:



Diseases related to Obstructive Jaundice

Symptoms & Phenotypes for Obstructive Jaundice

UMLS symptoms related to Obstructive Jaundice:


icterus, jaundice (not of newborn)

MGI Mouse Phenotypes related to Obstructive Jaundice:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.85 EDN1 F2 GGT1 GPBAR1 HGF IL6
2 homeostasis/metabolism MP:0005376 9.73 ALB CRP EDN1 F2 GGT1 GPBAR1
3 renal/urinary system MP:0005367 9.23 ALB EDN1 GGT1 GPBAR1 IL6 REN

Drugs & Therapeutics for Obstructive Jaundice

Drugs for Obstructive Jaundice (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lactulose Approved Phase 4 4618-18-2 11333
2
Ofloxacin Approved Phase 4 82419-36-1 4583
3
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
4
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
5 Topoisomerase Inhibitors Phase 4
6 Anti-Infective Agents Phase 4,Not Applicable
7 Anti-Bacterial Agents Phase 4,Not Applicable
8 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
9 Renal Agents Phase 4
10 Antibiotics, Antitubercular Phase 4,Not Applicable
11 Cytochrome P-450 Enzyme Inhibitors Phase 4
12 Anti-Infective Agents, Urinary Phase 4
13 Antitubercular Agents Phase 4
14
Ezetimibe Approved Phase 3 163222-33-1 150311
15
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
16
Simvastatin Approved Phase 3 79902-63-9 54454
17
Trioxsalen Approved Phase 2, Phase 3,Not Applicable 3902-71-4 5585
18
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
20
Methionine Approved, Nutraceutical Phase 3 63-68-3 6137
21 Calcium, Dietary Phase 3
22 Atorvastatin Calcium Phase 3 134523-03-8
23 Anticholesteremic Agents Phase 3
24 Lipid Regulating Agents Phase 3
25 Antimetabolites Phase 3
26 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
27 Hypolipidemic Agents Phase 3
28 Rosuvastatin Calcium Phase 3 147098-20-2
29 Nicotinic Acids Phase 3
30 Vitamin B3 Phase 3
31 Hematoporphyrin Derivative Phase 2, Phase 3,Not Applicable
32 Dihematoporphyrin Ether Phase 2, Phase 3,Not Applicable
33 Vitamins Phase 3
34 Micronutrients Phase 3
35 Vitamin B9 Phase 3
36 Folate Phase 3
37 Trace Elements Phase 3
38 Pharmaceutical Solutions Phase 3
39 Vitamin B Complex Phase 3
40 Vasodilator Agents Phase 3
41
Ursodeoxycholic acid Approved, Investigational Phase 2 128-13-2 31401
42
Neostigmine Approved, Vet_approved Phase 1, Phase 2 59-99-4 4456
43
Pancrelipase Approved, Investigational Phase 2,Phase 1 53608-75-6
44 Liver Extracts Phase 2,Phase 1
45 Gastrointestinal Agents Phase 2
46 Cholagogues and Choleretics Phase 2
47 Cholinesterase Inhibitors Phase 1, Phase 2
48 Anti-Inflammatory Agents Phase 1, Phase 2
49 Autonomic Agents Phase 1, Phase 2
50 Neurotransmitter Agents Phase 1, Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 59)
# Name Status NCT ID Phase Drugs
1 Randomised Trial Comparing Metal and Plastic Biliary Stents Stents for Palliating Malignant Jaundice Unknown status NCT00731419 Phase 4
2 Human Kidney Histopathology in Obstructive Jaundice Completed NCT01090193 Phase 4
3 Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents Completed NCT01315522 Phase 4
4 Antibiotics to Decrease Post ERCP Cholangitis Recruiting NCT03087656 Phase 4 Ceftriaxone;Levofloxacin
5 Preoperative Biliary Drainage for the Lower Malignant Obstructive Jaundice Unknown status NCT01744938 Phase 3
6 Palliative Biliary Stenting on the Quality of Life of Patients With Unresectable Carcinoma Gallbladder With Hiliar Block. Completed NCT00391183 Phase 2, Phase 3
7 A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383) Completed NCT02550288 Phase 3 Ezetimibe 10 mg;Atorvastatin 10 mg;Placebo for Ezetimibe 10 mg tablet;Placebo for Atorvastatin 10 mg capsule
8 A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384) Completed NCT02460159 Phase 3 EZ 10 mg/Atorva 20 mg FDC;EZ 10 mg/Atorva 10 mg FDC
9 A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832) Completed NCT02741245 Phase 3 Ezetimibe 10 mg;Rosuvastatin 2.5 mg;Placebo for Ezetimibe;Placebo for Rosuvastatin
10 MK-0524B Lipid Study (MK-0524B-063) Completed NCT00479882 Phase 3 Comparator: simvastatin;MK-0524A;Placebo;MK-0524B
11 Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024) Completed NCT00289900 Phase 3 MK-0524A;Atorvastatin;Simvastatin
12 Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma Recruiting NCT01755013 Phase 2, Phase 3
13 Remaxol® in Mechanical Jaundice of Non-malignant Origin Active, not recruiting NCT03418935 Phase 3 Remaxol (succinate + methionine + inosine + nicotinamide);Ringer's Solution
14 Remaxol® in Malignant Mechanical Jaundice Active, not recruiting NCT03416062 Phase 3 Remaxol®;Ringer's Solution
15 A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118) Terminated NCT01294683 Phase 3 Simvastatin;Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM);Extended Release (ER) niacin/laropiprant (N/LRPT);Placebo
16 Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar Obstruction Withdrawn NCT01622803 Phase 3
17 The Effect of Ursodeoxycholic Acid in Liver Functional Restoration of Patients With Obstructive Jaundice Unknown status NCT01688375 Phase 2 Ursodeoxycholic Acid
18 Role of Endoscopic RFA in Prolonging the Patency of Metal Stents in Patients With Malignant Obstructive Jaundice Unknown status NCT01275768 Phase 1, Phase 2
19 Cholinergic Anti-inflammatory Pathway in Prevention & Treatment of the SIRS in Patients With Jaundice After Operation. Unknown status NCT02279147 Phase 1, Phase 2 neostigmine methylsulfate,raceanisodamine hydrochloride
20 Evaluation of Preoperative Biliary Drainage Before Pancreatoduodenectomy Unknown status NCT01941342 Phase 2
21 Metal or Plastic Stents to Relieve Obstruction of Obstructive Jaundice Prior to Resection of Periampullary Tumors. Completed NCT02166840 Phase 2
22 Radiofrequency Ablation for Biliopancreatic Malignancy Completed NCT02468076 Phase 2
23 C-VISA BikDD: Liposome in Advanced Pancreatic Cancer Withdrawn NCT00968604 Phase 1
24 Immune Function in Patients With Obstructive Jaundice Unknown status NCT01367821
25 Percutaneous Transhepatic Cholangiography Versus Endoscopic Ultrasound Guided Biliary Drainage Unknown status NCT01686425 Not Applicable
26 A Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Malignant Hilar Biliary Obstruction Unknown status NCT02659852 Not Applicable
27 Efficacy and Safety of Endobiliary Radiofrequency Ablation by Using a Novel RF Catheter (ELRA®) on Maintaining the Patency of Endobiliary Metal Drainage in Patients With Malignant Biliary Strictures : A Double-arm Comparable Study Unknown status NCT02646514 Not Applicable
28 Intra-luminal Radiofrequency Ablation for Inoperable Malignant Biliary Stenosis Unknown status NCT02841800 Not Applicable
29 Evaluation of Immune Function in Biliary Atresia Children With Prolonged Jaundice Unknown status NCT00155194
30 Application of n-3 Fatty to Patient of Jaundice Completed NCT03376945 trail cohort;control cohort
31 Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers Completed NCT01134276 Not Applicable
32 Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma Completed NCT01506115 Not Applicable Photofrin
33 Endoscopic Versus Percutaneous Drainage For Hilar Block in Gall Bladder Cancer Completed NCT00409864 Not Applicable
34 Outcome of Carbon Dioxide Versus Air Insufflations During Endoscopic Retrograde Cholangiopancreatography (ERCP) Completed NCT01321203
35 Endoscopic Ultrasound-guided Biliary Drainage for Malignant Biliary Obstruction After Failed ERCP Completed NCT03510754
36 Malignant Obstruction ZILVER Against Routine Therapy (MOZART I) Completed NCT00196105 Not Applicable
37 Biliary Atresia, Hepatic Buffer Response and Sevoflurane Completed NCT02471209 Sevoflurane
38 Early Versus Late Cholecystectomy After Clearance of Common Bile Duct Stones Completed NCT02460315 Not Applicable
39 Endoscopic Retrograde Cholangiopancreatography (ERCP) Based Sampling of Indeterminate Bile Duct Strictures Completed NCT01580709 Not Applicable
40 Pre-treatment With Methylene Blue Prevent Peri-operative Reduced Systemic Vascular Resistance Recruiting NCT03406676 Not Applicable Methylene Blue
41 EUS Evaluation of CBD Diameter in Malignant Obstructive Jaundice Recruiting NCT03494023
42 Comparison of Metal and Plastic Stents for Preoperative Biliary Decompression Recruiting NCT01191814 Not Applicable
43 Cholangioscopic Assessment of Occluded Biliary Stent and Role of Biliary Radiofrequency Ablation Recruiting NCT03133026 Not Applicable
44 Trial Comparing Metal Versus Plastic Stents for Preoperative Biliary Decompression Recruiting NCT01675908 Not Applicable
45 Efficacy of Partial Covered Double Bare Metal Stent Compared to Uncovered Double Bare Metal Stent in Malignant Biliary Obstruction Recruiting NCT02937246 Not Applicable
46 RFA RCT for Pancreatic or Bile Duct Cancer Recruiting NCT02166190 Not Applicable
47 Study of Abdominal Drainage in LCBDE+PC Recruiting NCT03120754 Not Applicable
48 The Necessity of Bile Cultures in Patients With Acute Cholangitis Recruiting NCT02601417 Not Applicable
49 Single-operator Digital Cholangioscopy for the Diagnosis of Malignant and Benign Biliary Strictures Recruiting NCT03307382 Not Applicable
50 Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders Recruiting NCT01438385

Search NIH Clinical Center for Obstructive Jaundice

Cochrane evidence based reviews: jaundice, obstructive

Genetic Tests for Obstructive Jaundice

Anatomical Context for Obstructive Jaundice

MalaCards organs/tissues related to Obstructive Jaundice:

41
Liver, Pancreas, Lung, Kidney, Myeloid, T Cells, Neutrophil

Publications for Obstructive Jaundice

Articles related to Obstructive Jaundice:

(show top 50) (show all 1106)
# Title Authors Year
1
First report of hepatobiliary Mycobacterium avium infection developing obstructive jaundice in a patient with neutralizing anti-interferon-gamma autoantibodies. ( 30505452 )
2019
2
A Case of Eosinophilic Gastroenteritis in Which Obstructive Jaundice Developed due to Invagination of the Duodenal Wall. ( 29434146 )
2018
3
Obstructive jaundice as primary presentation of a stage IIE Non-Hodgkin lymphoma: A decision making process between advanced lymphoma and locally advanced/metastatic pancreatic adenocarcinoma. ( 29547849 )
2018
4
Efficacy of<sup>125</sup>I Versus Non-<sup>125</sup>I Combined with Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma with Obstructive Jaundice. ( 29305738 )
2018
5
A Surgically Resected Pancreatic Schwannoma with Obstructive Jaundice with Special Reference to Differential Diagnosis from Other Cystic Lesions in the Pancreas. ( 29606941 )
2018
6
Hepatobiliary and Pancreatic: Rare cause of obstructive jaundice by Trichosporon asahii. ( 29372610 )
2018
7
A Systematic Review and Meta-analysis of Intraluminal Brachytherapy Versus Stent Alone in the Treatment of Malignant Obstructive Jaundice. ( 29075881 )
2018
8
A patient with abdominal pain and obstructive jaundice. ( 29749334 )
2018
9
Post-operative care of interventional therapy for 40 liver cancer patients with obstructive jaundice. ( 29767833 )
2018
10
Elevated endogenous opioids in obstructive jaundice: The possible skin mechanisms. ( 29857894 )
2018
11
MicroRNA-29a mitigation of endoplasmic reticulum and autophagy aberrance counteracts in obstructive jaundice-induced fibrosis in mice. ( 29105510 )
2018
12
Spontaneous remission of obstructive jaundice in rats: Selection of experimental models. ( 29904412 )
2018
13
Pancreatic Burkitt's lymphoma presenting as an unusual cause of obstructive jaundice. ( 29696783 )
2018
14
Bile and circulating HMGB1 contributes to systemic inflammation in obstructive jaundice. ( 29907203 )
2018
15
Obstructive jaundice caused by an adenoma of the common hepatic duct. ( 29980303 )
2018
16
MicroRNA-29a mitigation of toll-like receptor 2 and 4 signaling and alleviation of obstructive jaundice-induced fibrosis in mice. ( 29366780 )
2018
17
Combined Effectiveness of Honey and Immunonutrition on Bacterial Translocation Secondary to Obstructive Jaundice in Rats: Experimental Study. ( 29786675 )
2018
18
Primary pancreatic lymphoma as a cause of obstructive jaundice. ( 29615287 )
2018
19
Pancreatobiliary fistula associated with intraductal papillary mucinous carcinoma accompanying obstructive jaundice: A case report. ( 29890488 )
2018
20
The Effect of Calcium Dobesilate on Liver Damage in Experimental Obstructive Jaundice. ( 29589984 )
2018
21
Duodenal mucinous adenocarcinoma presenting as ileus, obstructive jaundice and massive ascites: A case report. ( 29456851 )
2018
22
Malignant obstructive jaundice treated with intraluminal placement of Iodine-125 seed strands and metal stents: An analysis of long-term outcomes and prognostic features. ( 29748084 )
2018
23
Spironolactone rescues renal dysfunction in obstructive jaundice rats by upregulating ACE2 expression. ( 29882088 )
2018
24
Comparison of Endoscopic Ultrasonography Guided Biliary Drainage and Percutaneous Transhepatic Biliary Drainage in the Management of Malignant Obstructive Jaundice After Failed ERCP: Erratum. ( 29613967 )
2018
25
Adenosquamous Carcinoma of the Ampulla of Vater: A Rare Cause of Obstructive Jaundice. ( 29998166 )
2018
26
Safety and efficacy of irreversible electroporation in the treatment of obstructive jaundice in advanced hilar cholangiocarcinoma. ( 30057125 )
2018
27
Immunoglobulin G4 Sclerosing Cholangitis: An Unusual Cause of Obstructive Jaundice-Case Report and Literature Review. ( 30210896 )
2018
28
EUS-guided versus percutaneous biliary access in patients with obstructive jaundice due to gastric cancer. ( 30327252 )
2018
29
Obstructive jaundice caused by myeloid sarcoma in duodenal ampulla. ( 30253977 )
2018
30
Effect of sildenafil citrate on the liver structure and function in obstructive jaundice: An experimental study. ( 30023974 )
2018
31
A Rare Cause of Obstructive Jaundice: Cecal Herniation through the Foramen of Winslow. ( 30034928 )
2018
32
Afferent loop obstruction with obstructive jaundice and ileus due to an enterolith after distal gastrectomy: A case report. ( 30064120 )
2018
33
A Case of Obstructive Jaundice Caused by Metastasis of Ovarian Cancer to the Duodenal Major Papilla. ( 30090022 )
2018
34
Acute paracoccidioidomycosis with duodenal and cutaneous involvement and obstructive jaundice. ( 30148057 )
2018
35
Selection of biliary decompression method for treatment of obstructive jaundice in patients of older age groups. ( 30176629 )
2018
36
Preserving hepatic artery flow during portal triad blood occlusion improves regeneration of the remnant liver in rats with obstructive jaundice following partial hepatectomy. ( 30186418 )
2018
37
Obstructive jaundice secondary to a hepatic hydatid cyst. ( 30238755 )
2018
38
A case of obstructive jaundice due to early carcinoma of the cystic duct protruding into the common bile duct. ( 30308425 )
2018
39
Obstructive jaundice of a parasitic etiology. ( 30318892 )
2018
40
An unusual finding of obstructive jaundice-a case report and review of the literature. ( 30323942 )
2018
41
Obstructive jaundice due to a blood clot after ERCP: a case report and review of the literature. ( 30390657 )
2018
42
The pharmacokinetics of dexmedetomidine in patients with obstructive jaundice: A clinical trial. ( 30427948 )
2018
43
Transhepatic forceps biopsy combined with biliary drainage in obstructive jaundice: safety and accuracy. ( 30511177 )
2018
44
Pathophysiological consequences of obstructive jaundice and perioperative management. ( 29428098 )
2018
45
Treatment of pancreatic head cancer with obstructive jaundice by endoscopy ultrasonography-guided gastrojejunostomy: A case report and literature review. ( 29995808 )
2018
46
Safety and efficacy of n-3 fatty acid-based parenteral nutrition in patients with obstructive jaundice: a propensity-matched study. ( 30006616 )
2018
47
Obstructive Jaundice in a Patient with Polycystic Liver. ( 30013762 )
2018
48
Identification of bile survivin and carbohydrate antigen 199 in distinguishing cholangiocarcinoma from benign obstructive jaundice. ( 27874286 )
2017
49
Magnetic Resonance Cholangiopancreatography (MRCP) Evaluation of Obstructive Jaundice in Comparison with Endoscopic Retrograde Cholangiopancreatography (ERCP). ( 28588181 )
2017
50
Cholangiohydatidosis: an Infrequent Cause of Obstructive Jaundice and Acute Cholangitis. ( 28425414 )
2017

Variations for Obstructive Jaundice

Expression for Obstructive Jaundice

Search GEO for disease gene expression data for Obstructive Jaundice.

Pathways for Obstructive Jaundice

Pathways related to Obstructive Jaundice according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.09 CXCL8 HGF IL6 TNF
2
Show member pathways
12 CXCL8 EDN1 IL6 TNF
3
Show member pathways
11.97 ALB CRP F2 GGT1 IL6 TNF
4 11.84 CXCL8 IL6 TNF
5 11.83 ALB ALPP HGF IL6
6 11.78 EDN1 IL6 TNF
7 11.73 CXCL8 HGF IL6 TNF
8 11.72 CXCL8 IL6 TNF
9 11.68 CXCL8 IL6 TNF
10 11.62 CXCL8 EDN1 IL6 TNF
11 11.59 CXCL8 IL6 TNF
12
Show member pathways
11.5 CXCL8 IL6 TNF
13 11.43 CXCL8 IL6 TNF
14 11.34 CXCL8 IL6 TNF
15 11.25 ALB F2 TTR
16 11.25 CXCL8 HGF IL6 TNF
17 11.03 CXCL8 HGF IL6 TNF
18 10.82 CXCL8 EDN1 HGF IL6 TNF
19 10.54 CRP CXCL8 IL6 TNF

GO Terms for Obstructive Jaundice

Cellular components related to Obstructive Jaundice according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 ALB CRP CXCL8 EDN1 F2 HGF
2 extracellular space GO:0005615 9.4 ALB CRP CXCL8 EDN1 F2 GGT1

Biological processes related to Obstructive Jaundice according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.73 CXCL8 HGF IL6 TNF
2 cellular protein metabolic process GO:0044267 9.67 ALB F2 IL6 TTR
3 positive regulation of DNA-binding transcription factor activity GO:0051091 9.65 EDN1 IL6 TNF
4 defense response to Gram-positive bacterium GO:0050830 9.63 CRP IL6 TNF
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.58 F2 HGF TNF
6 embryonic digestive tract development GO:0048566 9.51 CXCL8 TNF
7 positive regulation of glial cell proliferation GO:0060252 9.49 IL6 TNF
8 positive regulation of smooth muscle cell proliferation GO:0048661 9.43 EDN1 IL6 TNF
9 acute-phase response GO:0006953 9.33 CRP F2 IL6
10 positive regulation of neuroinflammatory response GO:0150078 9.32 IL6 TNF
11 regulation of signaling receptor activity GO:0010469 9.17 CXCL8 EDN1 F2 HGF IL6 TNF
12 negative regulation of lipid storage GO:0010888 9.13 CRP IL6 TNF

Molecular functions related to Obstructive Jaundice according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.43 ALB CRP HGF SLC25A13 TNF TTR
2 cytokine activity GO:0005125 8.92 CXCL8 EDN1 IL6 TNF

Sources for Obstructive Jaundice

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....